Ertapenem: The new carbapenem 5 years after first FDA licensing for clinical practice

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 2, 2007, Pages 237-256

  Burkhardt, Olaf ^a,b   Derendorf, Hartmut ^b   Welte, Tobias ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Carbapenems; Ertapenem; Extended spectrum lactamases

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEFOTETAN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CIPROFLOXACIN; CREATININE; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; VANCOMYCIN;

ABDOMINAL INFECTION; ADNEXITIS; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANAEROBE; ANAEROBIC INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL FLORA; BACTERIAL INFECTION; BACTERIUM ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLORECTAL SURGERY; COMMUNITY ACQUIRED PNEUMONIA; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DIABETIC FOOT; DIARRHEA; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMYOMETRITIS; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GYNECOLOGIC INFECTION; HEMODIALYSIS; HUMAN; HYPOALBUMINEMIA; IATROGENIC DISEASE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LIVER FAILURE; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; OBESITY; PELVIC INFLAMMATORY DISEASE; PELVIS ABSCESS; PERITONITIS; PUERPERAL INFECTION; PYELONEPHRITIS; SEIZURE; SEPTIC ABORTION; SEX DIFFERENCE; SIDE EFFECT; SKIN ABSCESS; SKIN INFECTION; SURGICAL INFECTION; URINARY TRACT INFECTION; VEIN DISEASE; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; ENDOMETRITIS; FEMALE; HUMANS; PERITONITIS; PROTEIN BINDING; RENAL INSUFFICIENCY; SURGICAL WOUND INFECTION; URINARY TRACT INFECTIONS;

EID: 33846850229     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.2.237     Document Type: Article

References (110)

1. FELMINGHAM D, GRÜNEBERG RN: A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project. J. Antimicrob. Chemother. (1996) 38(Suppl. A): 1-57.
2. PFALLER MA, JONES RN, DOERN GV et al.: Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. (1998) 42:1762-1770.
3. TURNER PJ, GREENHALGH JM, EDWARDS JR et al.: The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int. J. Antimicrob. Agents (1999) 13:117-125.
4. PATERSON DL, ROSSI F, BAQUERO F et al.: In vitro susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J. Antimicrob. Chemother. (2005) 55:965-973.
5. RAMPHAL R, AMBROSE PG: Extended-spectrum β-lactamases and outcomes: current data. Clin. Inf. Dis. (2006) 42:164-172.
6. PATERSON DL: 'Collateral damage' from cephalosporin or quinolone antibiotic therapy. Clin. Inf. Dis. (2004) 38(Suppl. 4):341-345.
7. LIVERMORE DM: Minimising antibiotic resistance. Lancet Infect. Dis. (2005) 5:450-459.
8. BONFIGLIO G, RUSSO G, NICOLETTI G: Recent developments in carbapenems. Expert. Opin. Invest. Drugs (2002) 11:529-544.
9. ODENHOLT I: Ertapenem: a new carbapenem. Expert Opin. Investig. Drugs (2001) 10(Suppl. 2):23-28.
10. CUNHA BA: Errapenem. A review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today (2002) 38:195-213.
11. SHAH PM, ISAACS RD: Ertapenem, the first of a new group of carbapenems. J. Antimicrob. Chemother. (2003) 52:538-542.
12. LIVERMORE DM, SEFTON AM, SCOTT GM: Properties and potential of ertapenem. J. Antimicrob. Chemother. (2003) 52:331-344.
13. ZHANEL GG, JOHANSON C, EMBIL JM et al.: Ertapenem: review of a new carbapenem. Expert Rev. Anti Infect. Ther. (2005) 3:23-39.
14. KEATING GM, PERRY CM: Ertapenem: a review of its use in the treatment of bacterial infections. Drugs (2005) 65:2151-2178.
15. GOLDSTEIN EJ: Treatment of complicated community-acquired infections with ertapenem, the first group 1 carbapenem. Introduction. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):5-6.
16. HAMMOND ML: Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):7-9.
17. KOHLER J, DORSO KL, YOUNG K et al.: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob. Agents Chemother. (1999) 43:1170-1176.
18. SUMITA Y, FUKUKASAWA M, OKUDA T: Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J. Antibiot. (1990) 43:314-320.
19. FRIEDLAND I, MIXSON LA, MAJUMDAR A et al.: In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. J. Chemother. (2002) 14:483-491.
20. PANKUCH GA, DAVIES TA, JACOBS MR et al.: Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrob. Agents Chemother. (2002) 46:42-46.
21. HICKS PS, PELAK B, WOOD GL et al.: Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections. Clin. Microbiol. Infect. (2002) 8:753-757.
22. HILLIARD NJ, JOHNSON CN, ARMSTRONG SH et al.: In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int. J. Antimicrob. Agents (2002) 20:136-140.
23. PELAK BA, WOODS GL, TEPPLER H et al.: Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections. J. Chemother. (2002) 14:227-233.
24. PELAK BA, BARTIZAL K, WOODS GL et al.: Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin-structure infections. Diagn. Microbiol. Infect. Dis. (2002) 43:129-133.
25. PELAK BA, CITRON DM, MOTYL M et al.: Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. J. Antimicrob. Chemother. (2002) 50:735-741.
26. FUCHS PC, BARRY AL, BROWN SD: In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob. Agents Chemother. (2001) 45:1915-1918.
27. ROLSTON KV, LE BLANC BM, STREETER H et al.: In vitro activity of ertapenem against bacterial isolates from cancer patients. Diagn. Microbiol. Infect. Dis. (2002) 43:219-223.
28. LIVERMORE DM, CARTER MW, BAGEL S et al.: In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob. Agents Chemother. (2001) 45:1860-1867.
29. FUCHS PC, BARRY AL, BROWN SD: In vitro antimicrobial activities of a carbapenem, MK-0826 (L-7949, 345) and provisional interpretative criteria for disc tests. J. Antimicrob. Chhemother. (1999) 43:703-706.
30. REYNOLDS R, POTZ N, COLMAN M et al.: Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother. (2004) 53:1018-1032.
31. JONES RN, HUYNH HK, BIEDENBACH DJ et al.: Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. (2004) 54:144-154.
32. GOLDSTEIN EJ, CITRON DM, MERRIAM VC et al.: Comparative in vitro activities of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. J. Antimicrob. Chemother. (2001) 48:641-651.
33. JONES RN: In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. J. Chemother. (2001) 13:363-376.
34. GE Y, WIKLER MA, SAHM DF et al.: In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. (2004) 48:1384-1396.
35. LIVERMOORE DM, ALEXANDER S, MARSDEN B et al.: Activity of ertapenem against Neisseria gonorrhoeae. J. Antimicrob. Chemother. (2004) 53:280-281.
36. ALHAMBRA A, CUADROS JA, CACHO J et al.: In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J. Antimicrob. Chemother. (2004) 53:1090-1094.
37. ALDRIDGE KE: Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn. Microbiol. Infect. Dis. (2002) 43:181-186.
38. GOLDSTEIN EJ, CITRON DM, MERRIAM VC et al.: Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. (2000) 44:2389-2394.
39. BETRIU C, SANCHEZ A, PALAU ML et al.: In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains. Antimicrob. Agents Chemother. (2001) 45:2372-2374.
40. GOLDSTEIN EJ, CITRON DM, MERRIAM VC et al.: General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin-and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clin. Infect. Dis. (2002) 35:119-125.
41. GOLDSTEIN EJ, CITRON DM, MERRIAM VC et al.: Comparative in vitro activities of ertapenem. (MK-0826) against 469 less frequently identified anaerobes isolated from human infections. Antimicrob. Agents Chemother. (2002) 46:1136-1140.
42. HOELLMAN DB, KELLY LM, CREDITO K et al.: In vitro antianaerobic activity of ertapenem (MK-0826) compared with seven other compounds. Antimicrob. Agents Chemother. (2002) 46:220-224.
43. WEXLER HM, MOLITORIS D, FINEGOLD SM: In vitro activities of MK-0826 (L-749, 345) against 363 strains of anaerobic bacteria. Antimicrob. Agents Chemother. (2000) 44:2222-2224.
44. WEXLER HM: In vitro activity of ertapenem: review of recent studies. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):11-21.
45. PATERSON DL: Resistance in gram negative bacteria: Enterobacteriaceae. Am. J. Med. (2006) 119(Suppl. 1):20-28.
46. ODEN HOLT I, LOWDIN E, CARS O: In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. (1998) 42:2365-2370.
47. COTTAGNOUD P, PFISTER M, COTTAGNOUD M: Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or resistant Pneumococci in experimental meningitis. Antimicrob. Agents Chemother. (2003) 47:1943-1947.
48. CHOW JW, SHLAES DM: Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. J. Antimicrob. Chemother. (1991) 28:499-504.
49. BORNET C, DAVIN-REGLI A, BOSI C et al.: Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J. Clin. Microbiol. (2000) 38:1048-1052.
50. POIREL L, HERITIER C, TOLUN V et al.: Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. (2004) 48:15-22.
51. LINCOPAN N, MC CULLOCH JA, REINERT C et al.: First isolation of merallo-β-lactamase-producing multiresistent Klebsiella pneumoniae from a patient in Brazil. J. Clin. Microbiol. (2005) 43:516-519.
52. GIAKKOUPI P, XANTHAKI A, KANELOPOULOU M et al.: VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J. Clin. Microbiol. (2003) 41:3893-3896.
53. YAN JJ, KO WC, TSAI SH et al.: Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan. J. Clin. Microbiol. (2001) 39:4433-4439.
54. YIGIT H, QUEENAN AM, ANDERSON GJ et al.: Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. (2001) 45:1151-1161.
55. SMITH MOLAND E, HANSON ND, HERRERA VL et al.: Plasmid-mediated, carbapenem-hydrolyzing β-lactamase, KPC-2 in Klebsiella pneumoniae isolates. J. Antimicrob. Chemother. (2003) 51:711-714.
56. WOODFORD N, TIERNO JR PM, YOUNG K et al.: Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. (2004) 48:4793-4799.
57. BRATU S, LANDMAN D, HAAG R et al.: Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City a new threat to our antibiotic armamentarium. Arch. Intern. Med. (2005) 165:1430-1435.
58. BRATU S, TOLANEY P, KARUMUDI U et al.: Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. (2005) 56:128-132.
59. BRATU S, LANDMAN D, ALAM M et al.: Detecting of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother. (2005) 49:776-778.
60. MIRIAGOU V, TZOUVELEKIS LS, ROSSITER S et al.: Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class a carbapenemase KPC-2. Antimicrob. Agents Chemother. (2003) 47:1297-1300.
61. NIX DE, MAJUMDAR AK, DINUBILE MJ: Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):23-28.
62. MAJUMDAR AK, MUSSON DG, BIRK KL et al.: Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. (2002) 46:3506-3511.
63. WONG BK, SAHLY Y, MISTRY G et al.: Comparative disposition of [14C] ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica (2004) 34:379-389.
64. MUSSON DG, MAJUMDAR AK, HOLLAND S et al.: Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob. Agents Chemother. (2004) 48:521-524.
65. MUSSON DG, MAJUMDAR AK, BIRK K et al.: Pharmacokinetics of intramuscularly administered ertapenem. Antimicrob. Agents Chemother. (2003) 47:1732-1735.
66. PLETZ MWR, RAU M, BULITTA J et al.: Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob. Agents Chemother. (2004) 48:3765-3772.
67. BURKHARDT O, KUMAR V, KATTERWE D et al.: Ertapenem in critically ill patients with early-onset VAP: pharmacokinetics with special consideration on the free drug concentration. J. Antimicrob. Chemother. In press.
68. LAETHEM T, DE LEPELEIRE I, MCCREA J et al.: Tissue penetration by ertapenem, a parenteral carbapenem administered once-daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob. Agents Chemother. (2003) 47:1439-1442.
69. BURKHARDT O, BRUNNER M, SCHMIDT S et al.: Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J. Antimicrob. Chemother. (2006) 58:632-638.
70. BURKHARDT O, MAJCHER-PESZYNSKA J, BORNER K et al.: Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J. Clin. Pharmacol. (2005) 45:659-665.
71. BURKHARDT O, MAJCHER-PESZYNSKA J, BORNER K et al.: Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. Clin. Microbiol, Infect. (2005) 11(Suppl. 2):275.
72. WITTAU M, WAGNER E, KAEVER V et al.: Intra-abdominal tissue concentration of ertapenem. J. Antimicrob. Chemother. (2006) 57:312-316.
73. MERCK & CO., INC: Invanz® (ERTAPENEM SODIUM) prescribing information. Merck & Co., Inc., Whitehouse Station (NJ) USA (2006).
74. CHEN M, NAFZIGER AN, DRUSANO GL et al.: Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob. Agents Chemother. (2006) 50:1222-1227.
75. HOLLAND SD, MAJUMDAR AK, MUSSON DG et al.: Pharmacokinetics of ertapenem in renal insufficiency (RI). Clin. Pharmacol. Ther. (2001) 69:16.
76. MISTRY GC, MAJUMDAR AK, SWAN S et al.: Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J. Clin. Pharmacol. (2006) 46:1128-1138.
77. KUMAR V, BURKHARDT O, PLETZ M et al.: Comparison of pharmacodynamic target attainment of ertapenem in healthy volunteers and intensive care unit patients using Monte Carlo simulations. AAPS J. (2006) 8(Suppl. 2):3378.
78. LISTER PD, BLACK J: Pharmacodynamics of Ertapenem, imipenem, cefepime and ceftriaxone against Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases (ESBL) and plasma-encoded AmpC cephalosporinases. Clin. Infect. Dis. (2001) 33:1185.
79. XUAN D, BANEVICIUS M, CAPITANO B et al.: Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob. Agents Chemother. (2002) 46:2990-2995.
80. MAGLIO D, BANEVICIUS MA, SUTHERLAND et al.: Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine tigh model. Antimicrob. Agents Chemother. (2005) 49:276-280.
81. SCHUCK EL, DERENDORF H: Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev. Anti. Infect. Ther. (2005) 3:361-373.
82. CRAIG WA: Pharmacodynamics of antimicrobials: general concepts and applications. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds). Marcel-Dekker, New York (2002):1-22.
83. CRAIG WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. (1998) 26:1-12.
84. MOUTON JW, TOUZW DJ, HORREVORTS AM et al.: Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet (2000) 39:185-201.
85. FRIEDLAND I, MAJUMDAR A, MOTYL M et al.: Ertapenem is highly active against common clinical bacterial pathogens. Clin. Microbiol. Infect. (2002) 8(Suppl. 1):268.
86. LIU P, DERENDORF H: Antimicrobial tissue concentrations. Infect. Dis. Clin. North Am. (2003) 17:599-613.
87. PEA F, VIALE P, FURLANUT M: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet. (2005) 44:1009-1034.
88. MCQUADE MS, VAN NOSTRAND V, SCHARITER J et al.: Stability and compatibility of reconstituted ertapenem with commonly used IV infusion and coinfusion solutions. Am. J. Health Syst. Pharm. (2004) 61:38-45.
89. SOLOMKIN JS, YELLIN AE, ROTSTEIN OD et al.: Ertapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections: results of a double-blind, randomized comparative phase III trial. Ann. Surg. (2003) 237:235-245.
90. YELLIN AE, HASSETT JM, FERNANDEZ A et al.: Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int. J. Antimicrob. Agents (2002) 20:165-173.
91. DE LA PENA AS, ASPERGER W, KÖCKERLING F et al.: Efficacy and safety of ertapenem versus piperacillin/tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J. Gastrointest. Surg. (2006) 10:567-574.
92. TOMERA KM, BURDMANN EA, REYNA OG et al.: Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multi-center study. Antimicrob. Agents Chemother. (2002) 46:2895-2900.
93. JIMENEZ-CRUZ F, JASOVICH A, CAJIGAS J et al.: A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology (2002) 60:16-22.
94. ROY S, HIGAREDA I, ANGEL-MULLER E et al.: Ertapenem once-a-day versus piperacillin/tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multi-center, randomized, double-blind study. Infect. Dis. Obstet. Gynecol. (2003) 11:27-37.
95. VETTER N, CAMBRONERO-HERNANDEZ E, ROHLF J et al.: A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin. Ther. (2002) 24:1770-1785.
96. ORTIZ-RUIZ G, CABALLERO-LOPEZ J, FRIEDLAND IR et al.: A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin. Infect. Dis. (2002) 34:1076-1083.
97. ORTIZ-RUIZ G, VETTER N, ISAACS R et al.: Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicenter randomized, double-blind studies. J. Antimicrob Chemother. (2004) 53(Suppl. 2):59-66.
98. WOODS GL, ISAACS RD, MC CARROLL KA et al.: Ertapenem therapy for community-acquired pneumonia in the elderly. J. Am. Geriatr. Soc. (2003) 51:1526-1532.
99. FRIEDLAND IR, MCCARROLL KA, DINUBILE MJ et al.: Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia. Pulm. Pharmacol. Ther. (2004) 17:199-203.
100. GRAHAM DR, LUCASTI C, MALAFAIA O et al.: Ertapenem once-daily versus piperacillin/tazobactam four-times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multi-center study. Clin. Inf. Dis. (2002) 34:1560-1568.
101. GESSER RM, MC CARROL KA, WOODS GL: Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J. Infect. (2004) 48:32-38.
102. GESSER RM, MC CARROL KA, WOODS GL: Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin/tazobactam. Int. J. Antimicrob. Agents (2004) 23:235-239.
103. LIPSKY BA, ARMSTRONG DG, CITRON DM et al.: Ertapenem versus piperacillin/ tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blind, multi-center trial. Lancet (2005) 366:1695-1703.
104. GESSER RM, MC CARROL KA, TEPPLER H et al.: Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J. Antimicrob. Chemother. (2003) 51:1253-1260.
105. TELLADO J, WOODS GL, GESSER RM et al.: Ertapenem versus piperacillin/ tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin-structure, and acute pelvic infections. Surg. Infect. (2002) 3:303-314.
106. SOLOMKIN J, TEPPLER H, GRAHAM DR et al.: Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin/tazobactam. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):51-57.
107. ARGUEDAS A, WANG J, SNYDER T et al.: Safety and efficacy in a double-blind study of ertapenem versus ceftriaxone in pediatric patients with complicated urinary tract infections, community acquired pneumonia, or skin and soft tissue infections. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2005).
108. JOHNSON J, YELLIN A, HIGAREDA I et al.: Safety and efficacy in an open-label study of ertapenem versus ticarcillin/clavulanate in pediatric patients with complicated intra-abdominal infections or acute pelvic infections. 45th Intercience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2005).
109. TEPPLER H, GESSER RM, FRIEDLAND IR et al.: Safety and tolerability of ertapenem. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):75-81.
110. LEGUA P, LEMA J, MOLL J et al.: Safety and local tolerability of intramuscularly administered ertapenem diluted with lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Clin. Ther. (2002) 24:434-444.